Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Allurion Technologies ( (ALUR) ) just unveiled an announcement.
On March 6, 2026, the New York Stock Exchange moved to delist Allurion Technologies’ common stock and warrants after the company fell below the required $15 million average global market capitalization over 30 consecutive trading days, prompting an immediate suspension of NYSE trading and a transition of its securities to the OTCID Market. Allurion has appealed the NYSE decision, is trading under its existing symbols on the OTC platform, and has outlined a plan, catalyzed by its February 20, 2026 FDA approval for the Allurion Gastric Balloon System with the Smart Capsule, to regain listing compliance or relist on NYSE American while strengthening its balance sheet and funding U.S. commercialization, with management asserting that core operations and SEC reporting remain unaffected by the venue shift.
The most recent analyst rating on (ALUR) stock is a Buy with a $3.00 price target. To see the full list of analyst forecasts on Allurion Technologies stock, see the ALUR Stock Forecast page.
Spark’s Take on ALUR Stock
According to Spark, TipRanks’ AI Analyst, ALUR is a Neutral.
Overall score is held back primarily by weak financial performance: contracting revenue, large ongoing losses, heavy cash burn, and negative equity. Offsetting factors include improving cost control and constructive FDA/regulatory and balance-sheet restructuring progress discussed on the earnings call, plus moderately positive technical momentum. Valuation remains difficult to support due to negative earnings and no dividend yield provided.
To see Spark’s full report on ALUR stock, click here.
More about Allurion Technologies
Allurion Technologies, Inc., based in Natick, Mass., is a medical technology company focused on metabolically healthy weight loss solutions. Its lead product is the Allurion Gastric Balloon System, featuring the swallowable Allurion Smart Capsule, and the company is targeting the large U.S. obesity market following recent FDA approval.
Average Trading Volume: 2,783,028
Technical Sentiment Signal: Strong Sell
Current Market Cap: $3.2M
See more insights into ALUR stock on TipRanks’ Stock Analysis page.